- Home
- GAM vs NVCR Comparison
GAM vs NVCR Comparison
Compare GAM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- NVCR
- Stock Information
- Founded
- GAM 1927
- NVCR 2000
- Country
- GAM United States
- NVCR Switzerland
- Employees
- GAM N/A
- NVCR N/A
- Industry
- GAM Investment Managers
- NVCR Medical/Dental Instruments
- Sector
- GAM Finance
- NVCR Health Care
- Exchange
- GAM Nasdaq
- NVCR Nasdaq
- Market Cap
- GAM 1.5B
- NVCR 1.4B
- IPO Year
- GAM N/A
- NVCR 2015
- Fundamental
- Price
- GAM $63.97
- NVCR $13.33
- Analyst Decision
- GAM
- NVCR Buy
- Analyst Count
- GAM 0
- NVCR 7
- Target Price
- GAM N/A
- NVCR $28.07
- AVG Volume (30 Days)
- GAM 20.1K
- NVCR 1.6M
- Earning Date
- GAM 01-01-0001
- NVCR 10-30-2025
- Dividend Yield
- GAM 5.74%
- NVCR N/A
- EPS Growth
- GAM N/A
- NVCR N/A
- EPS
- GAM 11.67
- NVCR N/A
- Revenue
- GAM N/A
- NVCR $630,160,000.00
- Revenue This Year
- GAM N/A
- NVCR $6.68
- Revenue Next Year
- GAM N/A
- NVCR $7.01
- P/E Ratio
- GAM $3.95
- NVCR N/A
- Revenue Growth
- GAM N/A
- NVCR 14.58
- 52 Week Low
- GAM $37.32
- NVCR $10.87
- 52 Week High
- GAM $46.48
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- GAM 68.18
- NVCR 46.10
- Support Level
- GAM $62.25
- NVCR $13.53
- Resistance Level
- GAM $63.99
- NVCR $14.17
- Average True Range (ATR)
- GAM 0.87
- NVCR 0.58
- MACD
- GAM -0.02
- NVCR -0.11
- Stochastic Oscillator
- GAM 85.98
- NVCR 27.56
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.